‹ Go back to overview
Review of the SADC Pharmaceutical Business Plan Operational Plan
Financer:
DFID
Country:
Botswana, South Africa, Namibia, Swaziland, Lesotho, Zimbabwe, Malawi, Zambia, Mozambique, The Democratic Republic of The Congo, Seychelles, Madagascar, Mauritius, Tanzania, Angola
Field of Expertise:
Medical Products, Technologies; Policy/Strategy/DRA; Regional cooperation / harmonisation; Medical Products, Technologies; Policy/Strategy/DRA; Pharmaceutical markets (shaping, assessments, studies)
Narrative description of project:
The SADC Pharmaceutical Programme was approved in 2004. Its purpose is to “enhance the capacities of Member States to effectively prevent and treat diseases that are of major concern to public health in the Region”, including HIV and AIDS, Tuberculosis, Malaria and other communicable and non-communicable diseases. To operationalize the Pharmaceutical Programme a strategic business plan was developed covering the period 2007 to 2013. This was complemented in 2010 with a more detailed operational plan covering the last 3 years of the implementation period. In preparation of a final implementation review of the strategic business plan, a progress review was conducted to document progress and provide recommendations for updating the pharmaceutical business plan.
